Condition

Metastatic Breast Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 79 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials79

Recruiting23

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerNCT04529044 · 2026-06-30

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast CancerNCT06502691 · 2026-02-26

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast CancerNCT06860815 · 2026-01-30

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialNCT07158021 · 2026-01-22

Living Well With Advanced Breast CancerNCT07227038 · 2026-01-13

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung CancerNCT06910761 · 2025-05-05

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialNCT06500481 · 2025-03-04

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung CancerNCT06518057 · 2025-03-03

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast CancerNCT06260033 · 2024-07-23

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against CancerNCT07664579 · 2024-07-05

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsNCT06388122 · 2024-04-30

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · 2023-08-10

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung CancerNCT05746325 · 2023-04-07

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisNCT05376878 · 2022-12-21

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast CancerNCT05534438 · 2022-09-06

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNCT04090567 · 2020-07-28

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 InhibitorsNCT04526587 · 2020-07-03

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.NCT04305834 · 2020-03-25

Intravital Microscopy in Human Solid TumorsNCT03823144 · 2019-02-28

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast CancerNCT06217874 · 2014-06-05

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerNCT01174121 · 2010-08-26

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesNCT06982222 · 2026-10-01

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12

ACTIVE_NOT_RECRUITING

MBC Physical Activity StudyNCT06500858 · 2024-09-06

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast CancerNCT06557148 · 2024-08-13

ACTIVE_NOT_RECRUITING

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung CancerNCT06315296 · 2023-12-13

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With PaclitaxelNCT05751668 · 2023-11-02

ACTIVE_NOT_RECRUITING

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast CancerNCT06145399 · 2023-10-24

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsNCT04616248 · 2023-01-09

ACTIVE_NOT_RECRUITING

Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast CancerNCT05533320 · 2022-12-14

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line TherapyNCT05315687 · 2022-08-17

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic CancerNCT05215769 · 2022-03-30

ACTIVE_NOT_RECRUITING

Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast CancerNCT06206239 · 2022-03-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerNCT04673448 · 2021-10-18

ACTIVE_NOT_RECRUITING

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661 · 2021-08-09

ACTIVE_NOT_RECRUITING

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerNCT04108858 · 2021-05-20

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26

ACTIVE_NOT_RECRUITING

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA TrialNCT04756505 · 2021-03-07

18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesNCT04752267 · 2021-02-15

Apollo Device for Metastatic Breast Cancer (MBC)NCT04983342 · 2021-02-01

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast CancerNCT04418219 · 2020-12-21

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225 · 2020-12-08

Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease MonitoringNCT04906369 · 2020-11-16

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast CancerNCT04351230 · 2020-11-11

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE StudyNCT04316117 · 2020-09-15

ACTIVE_NOT_RECRUITING

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerNCT03939897 · 2020-06-17

ACTIVE_NOT_RECRUITING

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesNCT04585724 · 2020-06-12

Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer PatientsNCT04262518 · 2020-06-01

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast CancerNCT04120246 · 2020-04-08

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

Paclitaxel Therapeutic Drug Monitoring in Cancer PatientsNCT03987555 · 2019-11-11

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast CancerNCT03737695 · 2019-09-16

ACTIVE_NOT_RECRUITING

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerNCT03207529 · 2019-06-07

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyNCT04256941 · 2019-05-31

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma PatientsNCT03924466 · 2019-04-01

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerNCT03803761 · 2019-02-13

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisNCT03691493 · 2019-02-08

Common interventions

Leading sponsors

National Cancer Institute (NCI) 17 City of Hope Medical Center 9 M.D. Anderson Cancer Center 8 Mayo Clinic 8 Thomas Jefferson University 4 Emory University 3 Memorial Sloan Kettering Cancer Center 3 NRG Oncology 3 University of Washington 3 Ohio State University Comprehensive Cancer Center 2 OHSU Knight Cancer Institute 2 Roswell Park Cancer Institute 2 University of Southern California 2 Academic and Community Cancer Research United 1 Alliance for Clinical Trials in Oncology 1

Trial status mix

RECRUITING23

ACTIVE_NOT_RECRUITING18

COMPLETED15

WITHDRAWN10

TERMINATED8

SUSPENDED3

UNKNOWN2

Phase mix

PHASE232

PHASE125

NA9

PHASE34

EARLY_PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.